SynthesisBMC cancer2025
Paediatric acute myeloid leukaemia epidemiology, treatment approaches, and outcomes in africa: A review of the literature.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epigenetics and In Silico Transcriptome Analysis of Pediatric Acute Myeloid Leukemia.European journal of haematology · 2026Review
- Article
- Treatment outcomes and prognostic factors in children diagnosed with acute myeloid leukaemia in Uganda.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaediatric acute myeloid leukaemia (AML) is a challenging disease in low- and middle-income countries with limited African data. This study reviewed the existing literature regarding paediatric AML in Africa.
methodsA literature search was performed using PubMed, Embase, Google Scholar, Research4Life, and African Journals Online for published studies on paediatric AML in Africa, with keywords acute myeloid leukaemia, children, Africa, and country-specific names for all the African countries. The review included all abstracts and publications from Africa from January 2004 until January 2024, involving children between 0 and 17 years old with outcome data.
resultsOf 164 studies identified, 22 were included in the data analysis, with 2230 children included. Treatment regimens varied widely. Complete remission rates ranged between 23.1% and 88.9% (median 55.0%) for AML in general and between 72.6% and 95.0% for acute promyelocytic leukaemia (APL). The results also showed high rates of early deaths (5 - 96%; median 29.3%) and treatment-related mortality rates (11.3 - 47.1%; median 21.0%) among children with AML in the African setting. The five-year probability of event-free survival ranged from 14.8% for high-risk disease to 69.4% for APL. The five-year probability of overall survival ranged between 14% and 31.9% for non-APL (median 29.5%). Treatment abandonment varied between 3% and 50% (median 12.7%). Only 14 patients received a hematopoietic stem cell transplantation.
conclusionThere is limited data regarding paediatric AML and outcomes in Africa, with variable treatment regimens, treatment outcomes, early deaths, treatment-related mortality, and abandonment rates. Adapted treatment protocols adjusted to local settings should be implemented with improved supportive health care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.